Joachim M Baehring MD

Associate Professor of Medicine (Medical Oncology), of Neurology and of Neurosurgery; Clinical Program Leader, Brain Tumor Program, Smilow Cancer Hospital

Specialties & Subspecialties

Cancer Center, Yale: Brain Tumor Center | Hematology Program

Neurology: Stroke Center, Yale-New Haven | Brain Tumors and Neuro-Oncology

Neurosurgery: Neuro-Oncology

Education & Training

  • M.D., Johannes-Gutenberg-University of Mainz (1994)
  • Fellow, University Hospital Heidelberg / Germany , Molecular Oncology  (1994 - 1996)
  • Intern, Medical College of Pennsylvania/Philadelphia, PA , Internal Medicine  (1996 - 1997)
  • Resident, Hahnemann University Hospital Philadelphia, PA , Neurology  (1997 - 2000)
  • Fellow, Massachusetts General Hospital, Boston, MA , Neuro-Oncology  (2000 - 2002)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Chemotherapy of primary brain tumors (high-grade gliomas, central nervous system lymphoma); neurological complications of brain cancer; general neurology; molecular markers of cancer.


Cancers Treated

Brain


Board Certifications

  • Neurology, Board Certified (2001)

Clinical Trials

Conditions Study Title
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and Stomach A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Brain and Nervous System A Randomized Phase III open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)
Brain and Nervous System TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride with Hypofractionated Re-Irradiation Therapy in Treating Patients with Recurrent Glioblastoma Multiforme (GBM)

Edit Profile